Abstract
Background: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Methods: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases.
Results: There are currently seven classes of biologics that are available for the treatment of inflammatory arthritis, each inhibiting a different aspect of the immune-driven inflammatory pathway.
They include:
• Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol);
• Interleukin-1 (IL-1) receptor antagonists (anakinra);
• Interleukin-6 (IL-6) inhibition (tocilizumab);
• Interleukin-12/23 (IL23) inhibition (ustekinumab);
• Interleukin-17 (IL-17) inhibition (secukinumab);
• B-cell inhibition (anti-CD20, rituximab);
• T-cell costimulation inhibition (anti-CTLA-4, abatacept).
Conclusion: In this review, we will focus on the role of biologic drugs in the treatment strategies for inflammatory arthritis.
Keywords: Biologic drugs, TNF inhibitors, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, efficacy, safety.
Current Pharmaceutical Biotechnology
Title:Biologics in Inflammatory and Immunomediated Arthritis
Volume: 18 Issue: 12
Author(s): Michele M. Luchetti*, Devis Benfaremo and Armando Gabrielli
Affiliation:
- Dipartimento Scienze Cliniche e Molecolari, Sezione di Clinica Medica, Universita Politecnica delle Marche, Ancona,Italy
Keywords: Biologic drugs, TNF inhibitors, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, efficacy, safety.
Abstract: Background: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Methods: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases.
Results: There are currently seven classes of biologics that are available for the treatment of inflammatory arthritis, each inhibiting a different aspect of the immune-driven inflammatory pathway.
They include:
• Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol);
• Interleukin-1 (IL-1) receptor antagonists (anakinra);
• Interleukin-6 (IL-6) inhibition (tocilizumab);
• Interleukin-12/23 (IL23) inhibition (ustekinumab);
• Interleukin-17 (IL-17) inhibition (secukinumab);
• B-cell inhibition (anti-CD20, rituximab);
• T-cell costimulation inhibition (anti-CTLA-4, abatacept).
Conclusion: In this review, we will focus on the role of biologic drugs in the treatment strategies for inflammatory arthritis.
Export Options
About this article
Cite this article as:
Luchetti M. Michele*, Benfaremo Devis and Gabrielli Armando, Biologics in Inflammatory and Immunomediated Arthritis, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666171226151852
DOI https://dx.doi.org/10.2174/1389201019666171226151852 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Current Diabetes Reviews Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
Current Pharmaceutical Design Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry Chemokines and Persistent Inflammation in Rheumatoid Arthritis: Hunting for Therapeutic Targets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Identification of New Susceptibility Genes for Type 1 Diabetes: An Update
Current Immunology Reviews (Discontinued) The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases
Current Medicinal Chemistry Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy Studies on the Interaction of Papain with Human Placental Cystatin by Uv, Fluorescence and Cd Spectroscopy
Protein & Peptide Letters The Role of Mast Cells in the Structural Alterations of the Airways as a Potential Mechanism in the Pathogenesis of Severe Asthma
Current Pharmaceutical Design Mechanisms of Salt-Sensitive Hypertension
Current Hypertension Reviews Peptide Arrays for the Analysis of Antibody Epitope Recognition Patterns
Mini-Reviews in Organic Chemistry Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry The Dramatic Role of IFN Family in Aberrant Inflammatory Osteolysis
Current Gene Therapy Two Different Functions of Doxycycline Which is Both An Antimicrobial Agent and An Immune Modulator
Anti-Infective Agents in Medicinal Chemistry Rational Design and Development of RDP58
Current Pharmaceutical Design Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Rheumatoid Arthritis and Cardiovascular Risk: Between Lights and Shadows
Current Rheumatology Reviews Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology In Silico and 3D QSAR Studies of Natural Based Derivatives as Xanthine Oxidase Inhibitors
Current Topics in Medicinal Chemistry